OBJECTIVES: Despite scientific advances, pricing for many cancer medicines remains based upon the content of the delivery form (e.g. infusion vial), and size of patient. This can cause uncertainty of budget impact & cost effectiveness, and is not easily related to the value delivered. New methods which bring greater certainty of budget impact, cost effectiveness, and value should be evaluated. METHODS: